why choose us

First received: June 04, 2023

Clinical Trial: Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Immunotherapy

Study Type: INTERVENTIONAL


Official Title: A Single-arm Multicenter Phase II Clinical Trial of Cadunilumab (Anti-PD-1/CTLA-4) in Combination With or Without Chemotherapy in Second-line Treatment for Patients With Extensive Stage Small Cel

Brief Summary: This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer

Read more